AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
GLIMEPIRIDE USP
5 registrations across 4 African markets— 3 active
Markets with GLIMEPIRIDE USP
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Glimetab -2 tablets Tablet Uncoated | 🇿🇲Zambia | MMC Healthcare Limited | active | Jun 2031 |
| Glimestar 4 tablets Tablet Uncoated | 🇿🇲Zambia | Mankind Pharma Ltd | active | Mar 2030 |
| DIAPRIDE`_2 2MG UNCAOTED TABLETS UNCAOTED TABLETS | 🇲🇼Malawi | — | expired | Mar 2025 |
| GLIMERYL TABLETS TABLETS/3X10 | 🇳🇬Nigeria | OMAK PHARMA NIG LTD SUITE 1 & 2 | expired | Apr 2021 |
| GLIMERON-4 comprimé / 4 mg | 🇸🇳Senegal | AJANTA PHAMA LTD, AJANTA HOUSE, CHARKOP, KANDIVLI (W) MUMBAI, 400 067, INDE | active | — |
GLIMEPIRIDE USP in Africa — Regulatory Overview
GLIMEPIRIDE USP is registered across 4 African markets with 5 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Zambia, Malawi, Nigeria, Senegal. AfricaRegulatory refreshes this data daily from official government sources.
Of the 5 registrations, 3 (60%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.